Safety and effectiveness of reduced-dose apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: A sub-analysis of the STANDARD study - Journal of Cardiology
DVT Prophylaxis After Hip/Knee Surgery|ELIQUIS® (apixaban) Safety Info
Antithrombotic Management of Venous Thromboembolism: JACC Focus Seminar - ScienceDirect
Anticoagulation therapy in Atrial Fibrillation patients at high bleeding risk
Direct Oral Anticoagulants are High-Risk Medications with Potentially Complex Dosing | PSNet
Eliquis (Apixaban Tablets): Uses, Dosage, Side Effects, Interactions, Warning
DVT/PE Dosing | Rx ELIQUIS® (apixaban) Safety Info
CorConsult Rx - #Repost @ambcarerx ・・・ Oral Anticoagulants have many chronic indications, most commonly VTE treatment/prophylaxis, atrial fibrillation, and valvular heart disease. VTE & AF can both be treated with either warfarin
The New Oral Anticoagulants in Atrial Fibrillation: Once or Twice Daily? - American College of Cardiology
Update on the New Oral Anticoagulants - ppt video online download
Xa Inhibitors - Apixaban and Rivaroxaban Oral Xa ... | GrepMed
Apixaban for Extended Treatment of Venous Thromboembolism | NEJM
Apixaban (Eliquis®) – Drug-Drug-Interaction Considerations in COVID-19 Patients with Coagulation Abnormalities - Anesthesia Patient Safety Foundation
Target-Specific Oral Anticoagulants
Anticoagulation in Patients With COVID-19: JACC Review Topic of the Week - ScienceDirect
ELIQUIS® (apixaban) dosing for NVAF patients | ELIQUIS UK
Missouri Society of Health-System Pharmacists - Pharmacist Continuing Education: From DOACs to ROACs: Strategies for Reversing Oral Anticoagulants
DVT Prophylaxis After Hip/Knee Surgery|ELIQUIS® (apixaban) Safety Info
Eliquis: Package Insert / Prescribing Information - Drugs.com
Apixaban to Prevent Venous Thromboembolism in Patients with Cancer | NEJM
Target-Specific Oral Anticoagulants
ELIQUIS® (apixaban) dosing for DVT & PE patients | ELIQUIS UK
Lesson: Expanded Treatment Options for Venous Thromboembolism
Frontiers | Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy
Low-dose apixaban safe, effective as secondary prophylaxis for VTE in patients with cancer
Quick reference guide to apixaban | VHRM
